Skip to main content
. 2016 May;22(5):10.18553/jmcp.2016.22.5.573. doi: 10.18553/jmcp.2016.22.5.573

TABLE 2.

Clinical Characteristics of Women with Endometriosis Who Initiated LA

LA Plus Add-Back: NETA LA Plus Add-Back: Other Therapies LA Only P Value for LA Plus NETA vs. LA Plus Other P Value for LA Plus NETA vs. LA Only
n = 470 n = 681 n = 1,963
% n % n % n
Mean [SD] Deyo CCI 0.2 [0.6] 0.2 [0.6] 0.3 [0.7] 0.932 0.472
Comorbid conditions
  Anxiety 10.0 47 8.7 59 7.4 146 0.441 0.065
  Depression 9.6 45 9.8 67 7.8 154 0.882 0.219
  Dysmenorrhea 14.5 68 14.2 97 12.5 245 0.915 0.248
  Excessive or frequent menstruation 12.6 59 11.5 78 17.3 339 0.571 0.013
  Unspecified symptoms of female genital organs 42.3 199 40.5 276 36.7 720 0.539 0.023
  Abdominal/pelvic pain 35.3 166 32.9 224 32.0 628 0.393 0.167
Medications
  NSAIDs 40.0 188 40.2 274 36.6 718 0.936 0.168
  Opioids 55.5 261 54.5 371 50.4 990 0.724 0.047
  Androgens 0.9 4 1.3 9 0.4 7 0.458 0.151
  Antidepressants 33.2 156 33.2 226 27.5 539 0.999 0.013
  Hormonal contraceptives 27.0 127 64.2 437 22.8 448 < 0.001 0.054
  Hormone-releasing IUD or implant 0.4 2 0.7 5 0.8 16 0.508 0.376
  Depot medroxyprogesterone 4.7 22 2.1 14 4.4 87 0.012 0.815
  Other progestinsa 28.3 133 12.9 88 8.4 164 < 0.001 < 0.001

a Noncontraceptive norethindrone, noncontraceptive medroxyprogesterone, and progesterone.

CCI = Charlson Comorbidity Index; IUD = intrauterine device; LA = leuprolide acetate; NETA = norethindrone acetate; NSAIDs = nonsteroidal anti-inflammatory drugs;

SD = standard deviation.